All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Researchers from Chongqing Medical University have discovered novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors for the treatment of ALK-positive cancer.
